144 related articles for article (PubMed ID: 32025462)
1. Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives.
Wan Q; Deng Y; Huang Y; Yu Z; Wang C; Wang K; Dong J; Chen Y
ChemistryOpen; 2020 Feb; 9(2):176-182. PubMed ID: 32025462
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anti-tumor evaluation of novel steroidal glycoconjugate with furoxan derivatives.
Li H; Wang K; Wan Q; Chen Y
Steroids; 2019 Jan; 141():81-95. PubMed ID: 30521816
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor evaluation of novel hybrids of phenylsulfonylfuroxan and epiandrosterone/dehydroepiandrosterone derivatives.
Huang Y; Liu M; Meng L; Feng P; Guo Y; Ying M; Zhu X; Chen Y
Steroids; 2015 Sep; 101():7-14. PubMed ID: 26004429
[TBL] [Abstract][Full Text] [Related]
4. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents.
Liu MM; Chen XY; Huang YQ; Feng P; Guo YL; Yang G; Chen Y
J Med Chem; 2014 Nov; 57(22):9343-56. PubMed ID: 25350923
[TBL] [Abstract][Full Text] [Related]
5. Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents.
Hu X; Gao X; Gao G; Wang Y; Cao H; Li D; Hua H
Bioorg Med Chem Lett; 2021 May; 40():127952. PubMed ID: 33744443
[TBL] [Abstract][Full Text] [Related]
6. Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
Wang C; Xi D; Wang H; Niu Y; Liang L; Xu F; Peng Y; Xu P
Eur J Med Chem; 2020 Jun; 196():112271. PubMed ID: 32305784
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel hybrids of phenylsulfonyl furoxan and phenstatin derivatives as potent anti-tumor agents.
Huang X; Wang YS; Ma D; Wang YY; Bian SD; Zhang B; Qiao Y; He ZR; Lv M; Cai GL; Wang ZX; Liu XS; Shi JB; Liu MM
Eur J Med Chem; 2022 Feb; 230():114112. PubMed ID: 35065411
[TBL] [Abstract][Full Text] [Related]
8. Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity.
Bao N; Ou J; Xu M; Guan F; Shi W; Sun J; Chen L
Eur J Med Chem; 2017 Sep; 137():88-95. PubMed ID: 28558333
[TBL] [Abstract][Full Text] [Related]
9. Novel nitric oxide-releasing derivatives of pyranocarbazole as antitumor agents: Design, synthesis, biological evaluation, and nitric oxide release studies.
Zang Y; Huang L; Chen X; Li C; Ma J; Chen X; Zhang D; Lai F
Eur J Med Chem; 2022 Dec; 244():114832. PubMed ID: 36270090
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors.
Jin XY; Chen H; Li DD; Li AL; Wang WY; Gu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):955-972. PubMed ID: 31072147
[TBL] [Abstract][Full Text] [Related]
11. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
Han C; Huang Z; Zheng C; Wan L; Zhang L; Peng S; Ding K; Ji H; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4738-48. PubMed ID: 23668441
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation and molecular docking of new uracil analogs-1,2,4-oxadiazole hybrids as potential anticancer agents.
El Mansouri AE; Oubella A; Maatallah M; AitItto MY; Zahouily M; Morjani H; Lazrek HB
Bioorg Med Chem Lett; 2020 Oct; 30(19):127438. PubMed ID: 32736079
[TBL] [Abstract][Full Text] [Related]
13. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and in vitro anticancer activity of novel quinoline and oxadiazole derivatives of ursolic acid.
Gu W; Jin XY; Li DD; Wang SF; Tao XB; Chen H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4128-4132. PubMed ID: 28733083
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities.
Li N; Xu M; Bao N; Shi W; Li Q; Zhang X; Sun J; Chen L
Eur J Med Chem; 2018 Dec; 160():1-8. PubMed ID: 30316059
[TBL] [Abstract][Full Text] [Related]
16. Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
Zhang J; Wang X; Yang J; Guo L; Wang X; Song B; Dong W; Wang W
Eur J Med Chem; 2020 Jan; 186():111897. PubMed ID: 31761382
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity.
Massarico Serafim RA; Gonçalves JE; de Souza FP; de Melo Loureiro AP; Storpirtis S; Krogh R; Andricopulo AD; Dias LC; Ferreira EI
Eur J Med Chem; 2014 Jul; 82():418-25. PubMed ID: 24929292
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-donating derivatives of hederacolchiside A
Fang Y; Wang R; He M; Huang H; Wang Q; Yang Z; Li Y; Yang S; Jin Y
Bioorg Med Chem Lett; 2017 Jan; 27(1):98-101. PubMed ID: 27866816
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents.
Mochona B; Qi X; Euynni S; Sikazwi D; Mateeva N; Soliman KF
Bioorg Med Chem Lett; 2016 Jun; 26(12):2847-2851. PubMed ID: 27156770
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety.
Wang C; Xia G; Liu X; Zhang R; Chai Y; Zhang J; Li X; Yang Y; Wang J; Liu M
Bioorg Med Chem Lett; 2016 May; 26(9):2355-9. PubMed ID: 26995527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
